Belimumab: A BLyS-specific inhibitor for the treatment of systemic lupus erythematosus

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 143-149

  Dennis, G J ^a  

^a Department of Medical Affairs Human Genome Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; ANTIPYRETIC AGENT; AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ACINETOBACTER INFECTION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; B LYMPHOCYTE; BACTERIAL PNEUMONIA; BREAST CANCER; BRITISH ISLES LUPUS ASSESSMENT GROUP INSTRUMENT; BRONCHITIS; CELLULITIS; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INSOMNIA; LEUKOPENIA; LIMB PAIN; MIGRAINE; NAUSEA; OPPORTUNISTIC INFECTION; OVARY CANCER; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN CANCER; STOMACH CANCER; SUICIDAL IDEATION; SUICIDE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX; TACHYPHYLAXIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VIRAL GASTROENTERITIS; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84155163019     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.290     Document Type: Review

References (18)

1. Mok, C.C. & Lau, C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56, 481-490 (2003). (Pubitemid 36819418)
2. King, J. & Hahn, B. Systemic lupus erythematosus: modern strategies for management-a moving target. Best Prac. Res. Clin. Rheum. 21, 971-987 (2007). (Pubitemid 350194036)
3. Y ildirim-Toruner, C. & Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol. 127, 303-312; quiz 313 (2011).
4. Dall'Era, M. & Wofsy, D. Systemic lupus erythematosus clinical trials-an interim analysis. Nature Reviews Rheumatology, 5, 348-351 (2009).
5. Monneaux, F. & Muller, S. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res. Ther. 11, 234 (2009).
6. US Food and Drug Adminstration. FDA approves Benlysta to treat lupus. 〈http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489. htm〉 (2011).
7. Furie, R. et al. Biologic activity and safety of belimumab, a neutralizing anti-Blymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arth. Res. & Therapy, 10, R109 (2008).
8. Wallace, D.J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
9. Furie, R.A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143-1151 (2009).
10. Navarra, S.V. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Lancet, 377, 721-731 (2011).
11. Furie, R. et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits blys, in patients with systemic lupus erythematosus. Arthritis Rheum, in press.
12. van Vollenhoven, R. et al. Efficacy of belimumab in patients with systemic lupus erythematosus: focus on patients with low complement and positive anti-dsDNA-results from BLISS-52/BLISS-76. Presented at the European League Against Rheumatism 2011 Annual European Congress of Rheumatology.
13. Hiepe, F. et al. The mechanism of action of belimumab, a BLyS-specific inhibitor, is consistent with biomarker and vaccine results from the phase 3 BLISS studies. Presented at the European League Against Rheumatism 2011 Annual European Congress of Rheumatology, London, England.
14. Wallace, D. et al. Safety profile of belimumab, a blys-specific inhibitor, in patients with active systemic lupus erythematosus (SLE): pooled data from phase 2 and 3 studies. Presented at the American College of Rheumatology 2010 Annual Scientific Meeting, Atlanta, GA.
15. Chatham, W. et al. Effect of belimumab, a B lymphocyte stimulator-specific inhibitor on functional antibodies to pneumococcal, tetanus, and influenza vaccines. Presented at the American College of Rheumatology 2010 Annual Scientific Meeting, Atlanta, GA.
16. Petri, M.A. et al. Four-year experience of belimumab, a BLyS-specific inhibitor, in systemic lupus erythematosus (SLE) patients. Philadelphia, PA, ACR 2009. Abstr 2069.
17. Navarra, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Philadelphia, PA, ACR 2009. Abstr LB1.
18. Human Genome Sciences. BENLYSTA™ (belimumab) 〈http://www.hgsi. com/belimumab.html〉.